Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
Rapport bags $150M Series B just five months after nine-figure launch for epilepsy, psychiatry trials
Last year
Startups
Skye acquires Bird Rock Bio, weeks after Novo Nordisk says it will buy a CB1 developer
Last year
Startups
Deals
Andreessen Horowitz-backed startup lands $200M for AI-based drug discovery
Last year
R&D
AI
ARCH's latest biotech, targeting cancer recurrence, emerges from Columbia professor who worked on Biden's moonshot
Last year
Startups
Abcuro reels in $155M to test antibody's potential in rare muscle disease, setting biotech's 2026 BLA plans
Last year
Startups
Radiopharmaceutical biotech Radionetics in fundraising mode with $54.2M so far
Last year
Taysha raises $150M PIPE, shares single patient data on Rett syndrome gene therapy
Last year
R&D
Cell/Gene Tx
Maryland biotech Georgiamune nabs $75M to fund three cancer, autoimmune clinical trials
Last year
Startups
RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi 'to the next level'
Last year
Flagship startup Alltrna raises $109M for tRNA therapies that restore missing proteins
Last year
Mirati announces CEO resignation, then a $300M public offering after disclosing clinical plans
Last year
People
Nasdaq threatens to delist Taysha Gene Therapies
Last year
Poseida lines up another allogeneic CAR-T partner, allying with Astellas on solid tumors
Last year
Cell/Gene Tx
Playground Global, a16z back $26M seed for RNA editing startup aiming to address multiple mutations with single shot
Last year
Startups
Exclusive: Tech VC firm Playground Global deepens biotech focus, hires former a16z partner with next fund coming
Last year
People
Kyverna Therapeutics adds $60M to the bank as it prepares to showcase early CAR-T data in lupus nephritis
Last year
Cell/Gene Tx
Steve Jobs' son to lead Emerson Collective's oncology-focused VC firm Yosemite
Last year
Startups
CG Oncology reels in $105M crossover for potential late 2024 bladder cancer drug filing
Last year
Startups
Longwood launches startup Solu with drug candidates from GSK and $31M to start
Last year
Startups
PureTech Health snags $11.4M from DOD to test hormone drug in rare brain disease
Last year
Peter Hecht’s $81M pledge to salvage Cyclerion assets nabs Polaris support
Last year
Startups
UroGen nabs $120M to support potential 2024 NDA filing, launch of bladder cancer chemo gel
Last year
The veteran crew at Medicxi is back with a new $400M fund and an upbeat assessment of what's coming
Last year
Startups
Bioregnum
Jim Momtazee's Patient Square leads $150M+ addition to Kriya Therapeutics' 'mainstream' gene therapy ambitions
Last year
Startups
Cell/Gene Tx
First page
Previous page
28
29
30
31
32
33
34
Next page
Last page